Repurposing Clinically Safe Drugs for DNA Repair Pathway Modulation in CRISPR Genome Editing

Study Background and Research Question

Genome editing technologies, particularly CRISPR-Cas9, have transformed biomedical research and therapeutic development by enabling targeted induction of DNA double-strand breaks (DSBs) at specific genomic loci. DSBs can be resolved through several endogenous repair mechanisms, predominantly non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). The efficiency and fidelity of these pathways directly impact genome editing outcomes and therapeutic potential. A persistent challenge in both disease modeling and clinical gene therapy is achieving predictable repair outcomes and minimizing undesired mutagenesis. The referenced study addresses a key question: Can clinically approved drugs be repurposed to selectively modulate the choice of DNA repair pathways following CRISPR-induced DSBs in human cells (paper)?

Key Innovation from the Reference Study

The study's innovation lies in its high-throughput approach to drug repurposing for DNA repair pathway control. By systematically screening over 7,000 FDA-approved compounds, the authors provide the first large-scale resource mapping how clinically safe drugs influence the distribution of NHEJ, MMEJ, and HDR outcomes in CRISPR-edited human induced pluripotent stem cells (hiPSCs). Furthermore, the study demonstrates that pharmacological modulation of DNA repair can be exploited for synthetic lethality, potentially enabling targeted cancer therapies and precision genome engineering (paper).

Methods and Experimental Design Insights

The authors utilized a doxycycline-inducible Cas9 hiPSC line (409B2) to introduce DSBs at the FRMD7 genomic locus in the presence of individual drug treatments. The workflow included:

• Drug exposure during genome editing to assess acute effects on DNA repair outcome and cell survival.
• Cell viability assessment using a resazurin-based fluorescence assay to quantify the cytotoxic impact of each drug following CRISPR editing.
• Illumina next-generation sequencing of edited genomic loci to assign repair outcomes to NHEJ, MMEJ, or HDR pathways.

This single-replicate, high-content screen allowed for the quantification of pathway usage and relative modulation under diverse pharmacological conditions (paper).

Protocol Parameters

• assay | Next-generation sequencing | 100,000+ reads/sample | CRISPR repair outcome mapping | Ensures sufficient depth to distinguish pathway signatures | paper
• assay | Resazurin viability assay | 48 hours post-editing | Detects drug-induced cytotoxicity after DSB induction | Aligns viability with editing context | paper
• drug dosing | Single-compound screen | 7,240 conditions | Acute modulation of repair pathways | Enables broad repurposing assessment | paper
• cell type | hiPSCs (409B2 iCRISPR) | Human origin | Model for genome editing in therapeutically relevant cells | Reflects translational relevance | paper
• workflow_recommendation | Dantrolene sodium salt solubility | ≥12.2 mg/mL in DMSO | Ensures compatibility for cell-based assays | Facilitates reproducible delivery | product_spec

Core Findings and Why They Matter

The drug screen identified multiple compounds that significantly altered the distribution of DNA repair outcomes after CRISPR cutting. Notable findings include:

• Several drugs enhanced HDR frequency or suppressed NHEJ/MMEJ, supporting more precise template-driven edits.
• Silencing the estrogen receptor ESR2, in combination with NHEJ inhibition, produced a synergistic, 4.6-fold increase in HDR (paper).
• Drugs affecting aldehyde oxidase 1 (AOX1) and other DNA repair proteins influenced key decision points in repair pathway choice.
• Distinct compounds induced synthetic lethality when either NHEJ or HDR was blocked, revealing candidates for precision oncology applications (paper).

These results underscore the feasibility of using small molecules to steer genome editing outcomes and to selectively target cells with specific DNA repair deficiencies.

Comparison with Existing Internal Articles

Internal resources provide mechanistic context supporting the strategy of modulating DNA repair through small molecule intervention. For example, the article "Dantrolene Sodium Salt: Precision in Modulating RyR for DNA Repair and Calcium Signaling" discusses how ryanodine receptor antagonists, such as dantrolene sodium salt, enable precise control of calcium signaling, which is intimately linked to DNA repair processes. Similarly, "Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist" expands on how targeted RyR inhibition can enhance experimental reproducibility in CRISPR workflows and disease models. These insights align with the reference study’s demonstration that pharmacological agents can be leveraged to direct DNA repair pathway choice, although the internal articles focus more specifically on calcium signaling modulation and its downstream effects on repair fidelity and cell survival.

Limitations and Transferability

The reference study’s findings are robust within the context of hiPSC-based CRISPR editing. However, limitations include the use of single-replicate drug screens and the need to validate hits across diverse genomic loci, cell types, and editing platforms. The translation of these findings to primary cells, in vivo models, or clinical settings will require further validation. Additionally, while the study demonstrates broad drug effects on pathway choice, off-target pharmacology and long-term cellular impacts remain to be systematically addressed (paper).

Research Support Resources

For researchers seeking to implement DNA repair pathway modulation in CRISPR workflows, high-purity reagents with validated mechanisms of action are critical. Dantrolene, sodium salt (SKU B6329) is a potent ryanodine receptor antagonist with proven efficacy in modulating intracellular calcium release—a pathway with established links to DNA repair and cell stress responses (internal_article). Its calmodulin-dependent RyR2 inhibition supports advanced calcium signaling modulation for genome editing, neurodegenerative disease, and ischemia research workflows. For optimal results, researchers should follow solubility and storage guidelines as per the product specification. APExBIO offers quality control data to support reproducibility in experimental design.